It rebalances the TME towards an antitumor immune response by reducing the immunosuppressive myeloid derived cells and increasing the tumor fighting CD3+ T cells and, in particular, CD4+ T cells which in other studies is an indicator of an effective therapy. This evidence concerns the gene CD4 and neoplasm.